S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

LTRN Lantern Pharma Inc

4.41

-0.07 (-1.56%)

20 Jul 2024 - Closed

Delayed by 15 minutes

Annual Report to Security Holders (ars)

This regulatory filing also includes additional resources:
formars.pdf

Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more Lantern Pharma Charts.

Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024

Click Here for more Lantern Pharma Charts.

Lantern Pharma Inc. News

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 July 2024 (3 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 July 2024 (3 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 July 2024 (3 days ago) • Edgar (US Regulatory)

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
Wednesday 10 July 2024 (1 week ago) • Business Wire

Form 8-K - Current report
Tuesday 18 June 2024 (1 month ago) • Edgar (US Regulatory)

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
Wednesday 12 June 2024 (1 month ago) • Business Wire

Form EFFECT - Notice of Effectiveness
Tuesday 11 June 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Saturday 25 May 2024 (2 months ago) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Saturday 25 May 2024 (2 months ago) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Saturday 25 May 2024 (2 months ago) • Edgar (US Regulatory)

Oregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur...
Monday 13 May 2024 (2 months ago) • Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 10 May 2024 (2 months ago) • Edgar (US Regulatory)

More Lantern Pharma Inc. News Articles

Westpac Banking

Woodside Petroleum

Australian SE All Ordina...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions